Core Viewpoint - Archrock, Inc. has successfully completed the acquisition of Natural Gas Compression Systems, Inc. and NGCSE, Inc., which is expected to enhance its operational scale and customer relationships in the natural gas compression services sector [1][2]. Company Overview - Archrock is an energy infrastructure company focused on midstream natural gas compression, committed to safe and environmentally responsible practices in gas production, compression, and transportation [3]. Acquisition Details - The acquisition involved the issuance of approximately 2.251 million new common shares to NGCSE and a cash payment of $299 million funded through Archrock's ABL credit facility [2]. - The transaction is anticipated to be immediately accretive to Archrock's earnings per share and cash available for dividends per share in 2025 [2]. Strategic Implications - The acquisition is expected to deepen Archrock's operations in key regions and strengthen its position as a leading provider of natural gas compression services in the United States [2]. - The company aims to maintain a target leverage ratio between 3.0 and 3.5 times following the acquisition [2].

Financial Performance - Trisura Group reported a strong Operating ROE of 18.4% for Q1 2025, with Operating net income of $34.2 million or $0.70 per share, reflecting consistent execution of its strategy [1][5] - The quarterly Combined ratio was 82.7%, indicating strong underwriting performance, with a Loss ratio of 31.5% and an Expense ratio of 51.2% [2][27] - Net insurance revenue increased by 12.8% to $172.7 million compared to Q1 2024, driven by growth in Primary lines [4][13] Growth and Expansion - Trisura's Primary lines experienced significant growth of 28.1% in Q1 2025, contributing meaningfully to Underwriting income [2][5] - The company expanded its US Surety operations, achieving 33 state licenses and enhancing relationships with key distribution partners [2][5] Investment Income - Net investment income rose by 8.6% to $18.2 million in Q1 2025, supported by a larger investment portfolio [4][8] - The growth in investment income reflects the overall business growth and effective management of the investment portfolio [5][8] Capital Position - Trisura's book value reached a record $820 million, with a conservative debt-to-capital ratio of 10.7%, indicating flexibility for future growth [2][14] - The Minimum Capital Test ratio for the regulated Canadian subsidiary was 273%, comfortably exceeding the regulatory requirement of 150% [14]

– Topline histology data from ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials are expected in 1H 2027 and in 2028, respectively; each trial is designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (MASH) – – The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) has been fully enrolled and topline data are expected in 1Q 2026 – – Cash, cash equivalents, and marketable securities totaled $638.8 million as of March 31, 2025; complet ...

WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has published its Environmental, Social and Governance (ESG) report for 2025. As a company focused on optimizing meaningful engagement opportunities at critical junctures of the healthcare journey, we remain dedicated to aligning our mission with our responsibiliti ...

WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board, and Matt Pulisic, CFO, will discuss clinical-stage programs and upcoming milestones in a fireside chat at the Citizens Life Sciences Conference taking place May 7-8, 2025, in New York. The conversation with Biotech Equity Research Managing Director, Silvan Tuerkcan, PhD, is scheduled to be ...

Dosing cohort 3 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers and plan to initiate backfill cohorts in the second half of 2025Plan to provide a proof of concept data readout in the first half of 2026Cash of approximately $55.9 million expected to fund operations into the second half of 2026 BELTSVILLE, Md., May 01, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-clas ...

– NDA submitted in 1Q 2025 for ziftomenib for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation – – Data from Phase 1b/2 registration-directed trial of ziftomenib selected for oral presentation at ASCO Annual Meeting – – $45.0 million milestone payment earned for NDA submission under collaboration agreement with Kyowa Kirin – – First patients dosed in Phase 1 trial of ziftomenib plus imatinib in GIST – – $703.2 million in pro forma cash, together with anticipated collabor ...

COSTA MESA, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- El Pollo Loco Holdings, Inc. (Nasdaq: LOCO) today announced financial results for the 13-week period ended March 26, 2025. Highlights for the first quarter ended March 26, 2025 compared to the first quarter ended March 27, 2024 were as follows: Total revenue was $119.2 million compared to $116.2 million.System-wide comparable restaurant sales(1) decreased by 0.6%.Income from operations was $9.0 million compared to $9.7 million.Restaurant contribution(1) w ...

SAN JOSE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Zoom Communications, Inc. (NASDAQ: ZM) today announced it will release its financial results for the first quarter of fiscal year 2026 on Wednesday, May 21, 2025, after the market closes. A live Zoom Webinar of the event can be accessed at 2:00 pm PT / 5:00 pm ET through Zoom’s investor relations website at https://investors.zoom.com. A replay will be available approximately two hours after the conclusion of the live event. About ZoomZoom’s mission is to pr ...

MENLO PARK, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq: EXPO) today reported financial results for the first quarter of fiscal year 2025 ended April 4, 2025. “Exponent’s first quarter results exceeded expectations, reinforcing both the resilience of our diversified business model and the value we deliver,” said Dr. Catherine Corrigan, President and Chief Executive Officer. “Our failure analysis expertise drove increased dispute-related activities in the chemicals, transportation and uti ...